<DOC>
	<DOC>NCT01019473</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Chorea</mesh_term>
	<criteria>Huntington's disease (based on DNA testing polyQ &gt;36) with a UHDRS maximal chorea score of &gt;10 patient with concomitant Huntington's medication (antidepressants, neuroleptics, benzodiazepines) are allowed but the total daily dose and dosing regimen has to be stable for at least one months prior to randomization female patients without childbearing potential (postmenopausal or surgically sterilized), all patients must using a doublebarrier local contraception patients with marked cognitive impairment (MMSE less than 18), with presence of psychosis and/or confusional states patients with a history or presence of renal impairment and/or liver disease Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Huntington's disease</keyword>
	<keyword>Chorea</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>